Content area

|
|

Forebyggelse af herpes zoster med vaccination

Forfatter(e)
Kristian Kofoed1, Finn Rønholt2, Jan Gerstoft3 & Carsten Sand1 1) Dermato-venerologisk Afdeling, Bispebjerg Hospital, 2) Medicinsk Afdeling O, Herlev Hospital og 3) Epidemiklinikken, Rigshospitalet
Reference: 
Ugeskr Læger 2011;173(2):110-114
Blad nummer: 
Sidetal: 
110-114
Summary Prevention of herpes zoster by vaccination Ugeskr Læger 2011;173(2):110-114 Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged =50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Torben Albert Devantier | 21/02
2 kommentarer
af Turid Eva Klaveness Hansen | 21/02
1 Kommentar
af Dorte Lander Rasmussen | 21/02
1 Kommentar
af Gert Frank Thomsen | 17/02
1 Kommentar
af Kaare Rossel | 17/02
1 Kommentar
af Niels Rokkjær | 16/02
1 Kommentar
af Niels Egund | 15/02
2 kommentarer
af Astrid Hanna M. Schulze | 14/02
1 Kommentar